Epidermolysis bullosa (EB) is a rare, genetic and progressive skin blistering disease with no cure. In the most severe EB variants, children do not survive past the first year of life, and many die before they are 5 years old.
The goal of the project is to develop a systemic, tissue-specific therapeutic fusion protein, which would enable therapeutic drug molecule targeting to the skin. This would increase the therapeutic value in the target (“diseased”) organ, skin, with minimal adverse effects in the other parts of the body.
This project has a great potential for success since it brings a new and innovative possibility to cure skin diseases. The first target for the therapeutic is a rare, genetic and fatal skin disease epidermolysis bullosa (EB). This indication enables orphan drug status which brings many advantages for studying, developing and marketing of the drug.
Business Finland, Research to Business
Tero JärvinenProfessor, kliininen anatomia
Soili LehtonenPostdoctoral Research Fellow